Karyopharm rises on Bristol Myers collaboration for blood cancer therapy

Karyopharm Therapeutics

30/10/2023 12:56

** Shares of Karyopharm Therapeutics  KPTI.O  rise ~5.5% to
87 cents premarket
    ** Drugmaker says it is collaborating with Bristol Myers
Squibb  BMY.N  to evaluate a combination of KPTI's therapy
Xpovio and BMY's CELMoD for multiple myeloma patients
    ** Clinical trials expected to start in first half of 2024
    ** Up to last close, shares down 75.8% YTD

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))